US OptionsDetailed Quotes
DAVE241115C45000
- 4.00
- 0.000.00%
15min DelayClose Nov 7 15:59 ET
4.00High3.24Low
4.00Open4.00Pre Close18 Volume888 Open Interest45.00Strike Price7.05KTurnover129.37%IV6.73%PremiumNov 15, 2024Expiry Date0.91Intrinsic Value100Multiplier8DDays to Expiry3.09Extrinsic Value100Contract SizeAmericanOptions Type0.5814Delta0.0449Gamma11.70Leverage Ratio-0.2272Theta0.0049Rho6.80Eff Leverage0.0263Vega
Dave Inc Stock Discussion
Sign in to post a comment
$Dave Inc (DAVE.US)$
Buy the dip! My initial position is $34.3 but I added more at $37.83.
If the pullback gains power I want to add alot more next time.
Buy the dip! My initial position is $34.3 but I added more at $37.83.
If the pullback gains power I want to add alot more next time.
2
1
While the others take big losses selling everything they have, I feel the more rational decision is to do nothing.
The tech sector, specifically semiconductors and Ai/crypto companies, aren't going anywhere. NVDA isn't going to just shrug their shoulders and give up tomorrow.
So long as you have researched and relied on financials, I think it will all come back and probably stronger than ever.
In the meantime, I've added to a couple of "defense" stocks:
$ADMA Biologics (ADMA.US)$ : 58.8% U...
The tech sector, specifically semiconductors and Ai/crypto companies, aren't going anywhere. NVDA isn't going to just shrug their shoulders and give up tomorrow.
So long as you have researched and relied on financials, I think it will all come back and probably stronger than ever.
In the meantime, I've added to a couple of "defense" stocks:
$ADMA Biologics (ADMA.US)$ : 58.8% U...
4
3
Today grabbing
$Dave Inc (DAVE.US)$
PT $41+ SL $27
$Desktop Metal (DM.US)$
LT PT: $17+
$Hims & Hers Health (HIMS.US)$
LT PT: $39.27+
$Intel (INTC.US)$
PT: $50 SL: $25
Medium duration, 14-30 days min.
$Dave Inc (DAVE.US)$
PT $41+ SL $27
$Desktop Metal (DM.US)$
LT PT: $17+
$Hims & Hers Health (HIMS.US)$
LT PT: $39.27+
$Intel (INTC.US)$
PT: $50 SL: $25
Medium duration, 14-30 days min.
3
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings (SWVL.US)$718.40%
![]()
$Root Inc (ROOT.US)$564.60%
![]()
$Elevation Oncology (ELEV.US)$561.08%
![]()
$JanOne (JAN.US)$554.05%
![]()
$GeneDx Holdings (WGS.US)$520.71%
![]()
$Corbus Pharmaceuticals (CRBP.US)$513.25%
![]()
$AGBA Group (AGBA.US)$482.90%
![]()
$Janux Therapeutics (JANX.US)$431.22%
![]()
$Dave Inc (DAVE.US)$4...
A quick recap for the month ending April 30, 2024.
4
1
Despite strong revenue growth, Dave's low P/S ratio may indicate investor belief of underperformance in the broader industry. Shareholders may think recent performance has peaked, leading to lower selling prices. The low P/S ratio could signal price risks if medium-term revenue trends persist, but investors anticipate future revenue volatility.
Dave Inc.'s CEO, Jason Wilk, sees the recent transaction as a major advancement for the company, offering a unique chance to increase shareholder value. He remains confident in the company's ability to meet its growth and profitability goals in the future quarters.
$Dave Inc (DAVE.US)$ Something not right… it is now at 9.05
Despite strong revenue growth that outpaces the industry, Dave's P/S ratio is surprisingly low. This could suggest underlying risks to the company's future performance as investors may not be convinced the company can maintain its recent growth rates.
$Dave Inc (DAVE.US)$ what a bunch of clowns. Stellar revenue. and it will get better and better
No comment yet
Tonyco OP : o hey I remember you didn't you say there would be lambos